Mycophenolate mofetil

The main ingredient of this product is mycophenolate mofetil

Acyclovir: When MMF and acyclovir are taken simultaneously, the plasma concentrations of MPAG and acyclovir are higher than when either drug is taken alone. When renal function is impaired, the plasma concentrations of both MPAG and acyclovir increase. The two drugs are competitively excreted through the renal tubules, which may further increase the blood concentrations of both drugs. Antacids and magnesium hydroxide and aluminum hydroxide: The absorption of MMF is reduced when antacids are taken simultaneously. Cholestyramine: Healthy people first took cholestyramine 4 grams three times a day, and after four days, a single dose of MMF 1.5 grams was given, and the area under the curve of MPA decreased by 40%. Cyclosporine A: The pharmacokinetics of CsA are not affected by MMF. Ganciclovir: No pharmacokinetic cross-talk was observed between MMF and intravenous ganciclovir. Oral contraceptives: No interaction has been found between MMF and the oral contraceptive 1 mg norethindrone/35 micrograms ethinyl estradiol, but this is only a conclusion drawn from a single-dose study and does not rule out the possibility that long-term use of mycophenolate mofetil tablets will change the pharmacokinetics of oral contraceptives, which may lead to reduced efficacy of oral contraceptives. Sulfadimethoxazole: No effect on the bioavailability of MPA. Other interactions: Giving monkeys probenecid and MMF at the same time can increase the area under the curve of plasma MPAG by 3 times. For this reason, other drugs excreted through the renal tubules can compete with MPAG, thereby increasing the concentration of plasma MPAG or these drugs. Patients with immune response disorders should not be vaccinated with live vaccines. Antibody responses to other vaccinations may be eliminated.

The main ingredient of this product is mycophenolate mofetil.

Acyclovir: When MMF and acyclovir are taken simultaneously, the plasma concentrations of MPAG and acyclovir are higher than when either drug is taken alone. When renal function is impaired, the plasma concentrations of both MPAG and acyclovir increase. The two drugs are competitively excreted through the renal tubules, which may further increase the blood concentrations of both drugs. Antacids and magnesium hydroxide and aluminum hydroxide: The absorption of MMF is reduced when antacids are taken simultaneously. Cholestyramine: Healthy people first took cholestyramine 4 grams three times a day, and after four days, a single dose of MMF 1.5 grams was given, and the area under the curve of MPA decreased by 40%. Cyclosporine A: The pharmacokinetics of CsA are not affected by MMF. Ganciclovir: No pharmacokinetic cross-talk was observed between MMF and intravenous ganciclovir. Oral contraceptives: No interaction has been found between MMF and the oral contraceptive 1 mg norethindrone/35 micrograms ethinyl estradiol, but this is only a conclusion drawn from a single-dose study and does not rule out the possibility that long-term use of mycophenolate mofetil tablets will change the pharmacokinetics of oral contraceptives, which may lead to reduced efficacy of oral contraceptives. Sulfadimethoxazole: No effect on the bioavailability of MPA. Other interactions: Giving monkeys probenecid and MMF at the same time can increase the area under the curve of plasma MPAG by 3 times. For this reason, other drugs excreted through the renal tubules can compete with MPAG, thereby increasing the concentration of plasma MPAG or these drugs. Patients with immune response disorders should not be vaccinated with live vaccines. Antibody responses to other vaccinations may be eliminated.

Mycophenolate mofetil

Not yet clear